Rezultati pretraživanja
  1. 28. sij

    GmbH schließt Finanzierungsrunde über €11 Mio. ab mit (BIVF), , , und Starke Leistung in Tübingen! Gratulation zur Series B!

  2. 21. sij

    Congrats❕ Our company secures Series B Financing in excess of €11 Mio. to advance first drug candidate to the clinic. The company is developing a novel therapy for the treatment of acute and chronic liver diseases. ➡️

  3. 21. sij
  4. 21. sij
  5. 17. lis 2019.

    GmbH Announces Management Changes, Dr. Michael Lutz appointed as new CEO/Managing Director

  6. Raises €9M in Series A Financing. Read more:

  7. GmbH Raises €9 Million In A Series A Financing To Develop Kinase Inhibitors Fo... Read more:

  8. . raises €9M to develop regenerative therapeutics:

  9. €9M raised by toward developing regenerative treatments:

  10. 5. sij 2017.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.